In this issue of Cell, Hallikas et al. (2006) and Wei et al. (2006) describe different ways of identifying direct targets of transcription factors and their corresponding regulatory sequences in the genome. Although still under development, these studies provide an efficient way to decipher regulatory networks.
It has been generally accepted that after birth, the growth of new blood vessels (a process termed angiogenesis) relies on the sprouting of resident endothelial cells from preexisting vessels. However, evidence is now emerging that cells derived from the bone marrow may also contribute to postnatal angiogenesis. Most studies have focused initially on delineating the role of endothelial progenitor cells in this process. However, more recent data also support a model in which cells of the hematopoietic lineage are mobilized and then entrapped in peripheral tissues, where they function as accessory cells that promote the sprouting of resident endothelial cells by releasing angiogenic signals. The identity of signals in the peripheral tissues that retain these angio-competent cells mobilized from the bone marrow has remained an outstanding question. In this issue of Cell, Grunewald et al. (2006) propose that vascular endothelial growth factor (VEGF) recruits a heterogeneous mix of myeloid cells from the bone marrow to the blood, and a chemokine stromal-derived factor-1 (SDF-1) traps and correctly positions a subpopulation of circulating proangiogenic myeloid cells around the growing vessels in tissues (Figure 1 ). The proangiogenic cells promote endothelial cell sprouting by releasing angiogenic factors, such as matrix metalloproteinase-9 (MMP-9) (Grunewald et al., 2006) . Thus, entrapment of the proangiogenic subpopulation of bone marrow-derived cells-in addition to their mobilization-may be a key step in regulating adult neovascularization. In another paper in this issue of Cell, Foo et al. (2006) report that ephrin-B2 regulates the retention and positioning of another cell type, smooth muscle cells, around endothelial cells in the blood vessel wall. Therefore, manipulating entrapment signals may offer therapeutic opportunities to stimulate or inhibit angiogenesis.
Blood vessels consist of endothelial cells and smooth muscle cells. How then are hematopoietic cells relevant to endothelial cell sprouting? In fact, there is strong evidence to support a link between hematopoiesis and angiogenesis, and this relationship is evolutionarily conserved. Several primitive species, such as earthworms and fruit flies, have a rudimentary network of blood channels that are not lined by endothelial cells but rather are lined by hemocytes, a cell type belonging to the hematopoietic lineage. By analogy, the blood and blood vascular systems as well as hematopoiesis and angiogenesis are also intimately intertwined in mammals. Blood vessel cells and hematopoietic cells are not only in close physical proximity when they arise during development, but the endothelial and hematopoietic progenitors may even share a common ancestor, the hemangioblast. In the embryo, hematopoietic stem cells migrate into avascular areas and attract sprouting endothelial cells by releasing angiogenic factors, such as angiopoietin-1 (Takakura et al., 2000) .
Similarly, in the adult, myeloid progenitor cells expressing VEGFR-1 undergo extravasation (that is, move through the endothelial cell layer) to become positioned around vessels in tumors where they stimulate tumor angiogenesis also through release of angiogenic factors (Carmeliet and Luttun, 2001; Rafii and Lyden, 2003) . Tumor-associated macrophages, monocytes expressing Tie2, mast cells, T lymphocytes, neutrophils, and platelets have similar activities (De Palma et al., 2005) . Notably, monocytes and dendritic cells have even maintained some of the ancient plasticity of hemocytes and are able to transdifferentiate into endothelial-like cells. In a reciprocal manner, endothelial cells in the bone marrow may provide a vascular niche for quiescent hematopoietic stem cells, and regulate the proliferation of myeloid progenitors.
Thus, a number of hematopoietic cell types affect blood vessel growth, in many cases by releasing angiogenic signals as bystanders around sprouting endothelial cells. For these angiocompetent cells to perform the task of stimulating angiogenesis, there should be mechanisms to position and retain these cells at these peripheral sites. We know that angiogenic agents such as VEGF, placental growth factor (PlGF, a VEGF homolog) and angiopoietins, as well as chemokines and cytokines, such as monocyte chemoattractant protein-1 (MCP-1), stromal cell-derived factor-1 (SDF-1), granulocyte/macrophage colony stimulating
In this issue of Cell, Grunewald et al. (2006) examine the role of hematopoietic cells in the form ation of new blood vessels. They show that organspecific expression of vascular endothelial growth factor (VEGF) is sufficient to mobilize and recruit hematopoietic cells from the bone marrow to the blood, but retention of the proangiogenic subpopulation of hematopoietic cells in peripheral organs requires an additional factor, stromalderived factor 1 (SDF1).
factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), erythropoietin, interleukins (IL-3, -8, -17), Gro-β, and others can mobilize cells from the bone marrow to the peripheral blood (Carmeliet and Luttun, 2001; Orimo et al., 2005; Urbich and Dimmeler, 2004) . However, the nature of the signals in the peripheral tissues that retain the proangiogenic cells has remained elusive. In their new study, Grunewald et al. (2006) identify SDF-1 as a retention factor for angio-competent cells-perhaps the first of its kind.
By using genetic approaches to switch the expression of VEGF on and off in the heart or liver, Grunewald et al. (2006) show that an increase in VEGF expression in these organs induces robust angiogenesis by stimulating endothelial cell proliferation (Grunewald et al., 2006) . Based on our knowledge of this prototypic angiogenic factor, this finding was not at all unexpected and, at first sight, would seem to be attributable to a direct effect of VEGF on endothelial cells. However, upon closer inspection, the authors noticed, surprisingly, that these tissues became infiltrated with abundant bone marrow-derived monocytic cells, which they termed "recruited bone marrowderived circulating cells" (or RBCCs) (Figure 1 ). RBCCs were already present within 4 days, which is before the growth of new blood vessels. These RBCCs did not appear to be endothelial progenitor cells, because they did not line the vessel wall as do endothelial cells, but instead underwent extravasation around the growing blood vessels. This observation raised a provocative question: do these bone marrow-derived cells causally contribute to angiogenesis? Grunewald et al. used their genetic model to address this question in more detail.
In response to mobilization signals, such as VEGF, a heterogeneous mix of hematopoietic cells (progenitors and more committed cells alike) is mobilized from the bone marrow to the peripheral blood. Traditionally, researchers have tried to characterize the fraction of such circulating bone marrow-derived cells that are capable of stimulating tissue revascularization and regeneration, by analyzing their expression of distinct lineage markers and receptors (e.g., CD45, CD133, CD14, CD34, CD117, VEGFR-1, and others) (Rafii and Lyden, 2003; Urbich and Dimmeler, 2004) . As different subpopulations may have such activity, and complex combinations of several markers (often expressed in a strain-specific and an activation-dependent manner) must be used, variable and often conflicting results have been obtained concerning the identity of the angio-competent bone marrow-derived cell type. To circumvent this problem, Grunewald et al. (2006) took advantage of their genetic model to isolate RBCCs from the liver or heart. They reasoned that only the proangiogenic circulating bone marrow-derived cells would be entrapped and correctly positioned around growing vessels in these organs when stimulating angiogenesis-thus taking advantage of the functional filter built in by nature. The RBCCs expressed VEGFR-1, explaining why they were recruited in response to VEGF. They also expressed typical myeloid markers such as CD45, CX3CR1, and CD11b. Thus, of all the circulating cells mobilized from the bone marrow into the peripheral blood, a selection of angiocompetent bone marrow-derived myeloid cells seemed to be retained in peripheral tissues in response to VEGF. Because VEGF expression was upregulated uniformly throughout the (1) In response to overexpression of VEGF in the liver, a heterogeneous mix of cells is recruited from the bone marrow to the peripheral blood (2). Amongst these cells are the RBCCs (recruited bone marrow-derived circulating cells). (3) VEGF overexpression in the liver also induces the expression of SDF-1 in mural cells around blood vessels. As a result, RBCCs expressing CXCR4 (blue), the receptor for SDF-1, are entrapped and correctly positioned around the vessels expressing SDF-1. (4) This subpopulation of RBCCs stimulates endothelial cell sprouting by releasing matrix metalloproteinase-9 (MMP-9) and other angiogenic factors.
liver and heart, this finding begged the question as to how this particular subfraction of cells was entrapped and precisely positioned around the emerging vasculature in these organs.
When analyzing the gene expression profile of the RBCCs, the authors noticed that the vast majority of these recruited cells expressed CXCR4, a receptor for the chemokine CXCL12, also known as SDF-1 (Grunewald et al., 2006) . Indeed, SDF-1 was minimally expressed in quiescent tissues, but when VEGF expression was turned on experimentally via the conditional genetic switch, the expression of SDF-1 increased markedly in perivascular fibroblasts and smooth muscle cells. SDF-1 was also induced in ischemic, inflamed, and malignant tissues in a VEGF-dependent manner. Moreover, the CXCR4 inhibitor AMD3100 abrogated the entrapment of RBCCs in tissues overexpressing VEGF. Although RBCCs showed a strong chemotactic response to SDF-1 in vitro, overexpression of SDF-1 alone, without concomitant expression of VEGF, was insufficient to retain RBCCs. However, overexpression of SDF-1 prevented the egress of RBCCs from VEGF-overexpressing tissues when VEGF expression was switched off. This provided strong evidence that SDF-1 is a "retention" or "entrapment" signal rather than a chemoattractant cue. Grunewald et al. (2006) also provide evidence that RBCCs are indeed angio-competent cells by showing that isolated RBCCs (or their conditioned medium) stimulated vessel sprouting in vitro, and preventing their retention using the CXCR4 inhibitor blocked angiogenesis in vivo. Further analysis revealed that RBCCs release MMP-9, a proteinase that facilitates endothelial cell sprouting; additional angiogenic factors are also likely to be released. Moreover, transplantation of RBCCs augmented neovascularization during the healing of skin wounds, providing strong evidence that RBCCs are angio-competent.
As is often the case, innovative concepts raise questions. For instance, what other factors besides SDF-1 retain angio-competent bone marrowderived cells in peripheral tissues? Are proangiogenic cells also entrapped by other signals, such as those involved in the retention of hematopoietic stem cells in the bone marrow or those that retain other tissue progenitors in their niches? Candidate retention signals include membrane-bound Kit ligand that binds to the cKit receptor, fibronectin and VCAM-1 that bind to β1 integrins, and angiopoietin-1 that interacts with Tie-2, to name a few (Quesenberry et al., 2005) . Does the retention by SDF-1 represent a general mechanism that is also operational in ischemia, healing, and malignancy? In contrast to the findings in the Grunewald study, others have shown that SDF-1 is also a mobilization signal, capable of recruiting CXCR4-positive progenitor cells into hypoxic tissues (Ceradini et al., 2004) . Does ischemia induce other signals that modify the activitiy of SDF-1? What is the precise interplay between mobilization signals (which recruit cells from the bone marrow into the blood) and entrapment signals (which capture cells in tissues)? Considering the similarities between hematopoiesis and angiogenesis, do other cytokines such as GM-CSF, G-CSF, erythropoietin, and thrombopoietin also recruit RBCCs? And what is the association between endothelial cells and CXCR4, whose expression is upregulated in ischemia: does this provide another amplification mechanism to stimulate endothelial cell growth when SDF-1 expression increases?
The elegant study by Grunewald et al. (2006) supports the emerging concept that an optimal angiogenic response not only relies on angiogenic signals that are released locally, but also requires amplification of this local response by mobilization and entrapment of an angio-competent subpopulation of circulating bone marrowderived support cells, which release additional angiogenic factors. This close link between angiogenesis and hematopoiesis and the identification of SDF-1 as a retention signal for angiocompentent bone marrow-derived cells opens attractive therapeutic avenues. Blocking SDF-1/CXCR4 signaling would be expected to inhibit angiogenesis in pathological conditions. Indeed, recent studies reveal that anti-SDF-1 antibodies reduce neovascularization in the eye (Butler et al., 2005) .
There are other examples of cell retention in the vasculature. Pericytes and smooth muscle cells, together known as mural cells, are entrapped around endothelial cells and have an accessory role in vessel growth (for instance, by releasing SDF-1) as well as in vessel maturation and stability (Carmeliet, 2003) . Progenitors of these mural cells are recruited to the nascent vasculature, where they differentiate and make close contact with and cover up endothelial cells. Previous studies have revealed the importance of PDGF-BB and angiopoietin-1 in recruiting mural cells around endothelial cells (Carmeliet, 2003) . In a complementary paper in this issue of Cell, Foo et al. (2006) provide genetic evidence that the expression of ephrin-B2 (a ligand for Eph receptor tyrosine kinases; Carmeliet and Tessier-Lavigne, 2005 ) by mural cells is important for their normal positioning and retention around blood vessels. In the absence of ephrin-B2, hypermotile smooth muscle cells show numerous lammelipodial protrusions in a nonpolarized and random fashion, which prevents them from making stable contacts and from spreading over endothelial cells. Thus, several mechanisms exist to entrap and position distinct cell types correctly in the growing vasculature: ephrins provide guided navigation and contact formation, whereas SDF-1 provides a retention signal. Regardless of the mechanistic details, studies such as Grunewald et al. (2006) and Foo et al. (2006) highlight the importance of cell entrapment in the life of a blood vessel.
The identification of downstream targets of regulatory factors is required to understand cellular responses to environmental and developmental cues. Precise control of gene expression is achieved through regulators such as microRNAs and transcription factors (He and Hannon, 2004; Pabo and Sauer, 1992) . Which genes are controlled by gene-specific transcription factors is partly determined by the DNA binding domain of these proteins. This domain allows the transcription factor to bind to specific DNA motifs in the vicinity of target genes. In theory, the availability of whole genome sequences should have made the job of finding transcription factor targets straightforward, for example, by allowing the location of recognition motifs to be simply looked up in the genome sequence. In practice, the task of determining transcription factor targets is still daunting, especially for organisms with complex genomes. Two papers in this issue of Cell (Hallikas et al., 2006; Wei et al., 2006) describe different ways of locating direct targets of transcription factors and their corresponding regulatory regions. The studies focus on transcription factors that are important for development and oncogenesis. The results underscore the importance of such work and indicate that there is still much to be discovered about even well-characterized transcription factors. Additionally, these results emphasize that combinations of different approaches will be required for the complete determination of regulatory networks.
Prior to the availability of whole genome sequences, methods for determining transcription factor targets were cumbersome. Such studies usually began by studying easily accessible proximal promoter sequences of a candidate target gene. Important regulatory DNA motifs were determined by mutating promoter sequences (promoter-bashing). This was followed by arduous hit-or-miss approaches such as electrophoretic mobility shift assays, biochemical purification, or expression cloning to identify the corresponding transcription factors. The availability of whole genome sequences has reversed this process and has made it possible to develop more exhaustive search methods.
The first contribution of whole genome sequences for finding transcription factor targets has been the development of microarray technology to measure mRNA expression (Young, 2000) . This can identify all genes that exhibit significant changes in mRNA levels upon inactivation of a transcription factor. The degree to which all direct targets are found depends on functional redundancy and whether the particular developmental stage or growth condition being studied completely covers the role of the transcription factor. The portion of such genes that actually represents direct targets is dependent on the number and the nature of indi-
